Pharos iBio will collaborate with the team of Professor Shin Sang-joon of the Department of Medical Oncology at Yonsei Cancer Center to conduct the translational study of PHI-501 under development for treating solid tumors.PHI-501 is a pipeline of solid tumor therapeutics in preclinical development.
Medytox has encountered a significant setback as the U.S. FDA has declined the biologics license application (BLA) for its innovative non-animal liquid botulinum toxin product, MT10109L, aimed at reducing moderate to severe glabellar (forehead) and lateral canthal (crow's feet) lines.The refusal, da
AriBio said Monday that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has formally approved POLARIS-AD, a global phase 3 clinical trial of AR1001, an oral treatment for Alzheimer's disease.AriBio plans to initiate the phase 3 trial in the U.K. before the end of the first quarte
The Korean government has made a formal proposal to the nation's medical community, urging them to appoint representative members to engage in discussions on critical issues such as the expansion of medical school quotas and the cessation of ongoing collective actions, including strikes and mass res
The first FGFR inhibitor for bladder cancer, Balversa (erdafitinib), will soon be launched in Korea.According to industry sources on Monday, Janssen Korea is gearing up to release Balversa without reimbursement in late March.Balversa is an FGFR (fibroblast growth factor receptor) inhibitor approved
The role of artificial intelligence (AI) is growing in the healthcare field. There are a lot of movements to incorporate AI. As global big tech companies, including Google and Microsoft, have made strides in healthcare AI, the area has evolved to the point where it is applied to real-world healthcar
Celltrion once again demonstrated the competitiveness of its Remsima SC at the 2024 European Crohn's and Colitis Organization (ECCO) congress in Stockholm, Sweden, from last Wednesday to Saturday by receiving favorable reviews from overseas medical professionals.At the ECCO, attended by more than 8,
GC Cell has signed an agreement to transfer the processing technology of its flagship anticancer immune cell therapy, Immuncell-LC Injection, to BioCentriq, its U.S. affiliate, and a cell therapy CDMO company.Through this process technology transfer cooperation, GC Cell and Biocentriq expect to prov
JW Shinyak said Monday it has signed a collaborative research agreement with C&C Research Laboratories, a subsidiary of JW Pharmaceutical, to develop innovative anticancer cell therapies.Under the agreement, JW Shinyak will develop a new CAR-NK cell therapy targeting solid tumors with C&C Research L
Samsung Bioepis said that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Pyzchiva, also known as SB17, a biosimilar candidate referencing Stelara, last Sunday. This biosimilar, referencing Janssen's Stelara (ingredient: uste
Pediatric leukemia is the most common cancer among children and adolescents.Most cases of pediatric leukemia manifest acutely, necessitating prompt intervention and treatment upon symptom onset. So what should you do when you notice symptoms in your child?We heard from Professor Hong Kyung-taek of S
CKD Bio said it has confirmed the non-inferiority of CKDB-501A, aimed at improving moderate to severe frown lines, compared to Botox through a phase 3 clinical trial's topline results.The analysis of the data revealed that the improvement rate for frown lines when frowning was 80.69 percent (117 out
The government fully allowed contactless medical treatment starting Friday in response to the medical community's collective action in protest against increasing the medical school enrollment quota.The permission will continue until the end of the doctors' strike. Telemedicine will be allowed at all
A new proposal for the expansion of medical school quotas by Professor Shin Young-seok of the Korea University Graduate School of Public Health, the principal researcher who previously provided the basis for the government's plan to increase the number of medical students by 2,000, is drawing signif
LG Chem said Friday that the company opened an aesthetic “Solution Lab Center" in Caiting Hospital, which specializes in cosmetic surgery in Shanghai, to expand expand its educational support for YVOIRE (LG Chem's hyaluronic acid filler’s brand name) customers in China.LG Chem’s Executive Vice Presi
GC Cell said that its U.S. affiliate, Artiva Biotherapeutics, has received fast-track designation from the U.S. FDA for their investigational lupus nephritis treatment, AlloNK (development code name: AB-101).The fast track designation is intended to facilitate the development and expedite the review
AbbVie's oral migraine prophylaxis Aquipta (atogepant) met its primary endpoint in a phase 3 clinical trial of patients who failed prior oral prophylaxis, reducing the average number of migraine days per month.AbbVie Korea said Friday that the full results of the phase 3 ELEVATE study were published
A typhoid conjugate vaccine developed by SK bioscience has received the World Health Organization's (WHO) Pre-Qualification (PQ) certification, a green light to enter new overseas markets.SK bioscience said Friday that its typhoid conjugate vaccine, SKYTyphoid Multi-Injection (NBP618 in the project
Janssen has been delaying the Korean launch of its FGFR (fibroblast growth factor receptor) inhibitor Balversa (erdafitinib) for over a year, making many watchers wonder what's happening.Janssen received approval for Balversa on Nov. 24, 2022, from the Ministry of Food and Drug Safety (MFDS).Balvers
At a government-business meeting early this week, the Ministry of Food and Drug Safety (MFDS) announced its intention to support exporting Korean medical products based on regulatory harmonization. Welcoming the move, pharmaceutical companies made several requests to open the way for exporting their